OCUP vs. CLRB, GTHX, RIGL, GALT, ATOS, SGMT, RZLT, ALIM, PRQR, and MCRB
Should you be buying Ocuphire Pharma stock or one of its competitors? The main competitors of Ocuphire Pharma include Cellectar Biosciences (CLRB), G1 Therapeutics (GTHX), Rigel Pharmaceuticals (RIGL), Galectin Therapeutics (GALT), Atossa Therapeutics (ATOS), Sagimet Biosciences (SGMT), Rezolute (RZLT), Alimera Sciences (ALIM), ProQR Therapeutics (PRQR), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.
Cellectar Biosciences (NASDAQ:CLRB) and Ocuphire Pharma (NASDAQ:OCUP) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, community ranking, institutional ownership, valuation and dividends.
Cellectar Biosciences presently has a consensus target price of $20.00, indicating a potential upside of 547.25%. Ocuphire Pharma has a consensus target price of $18.75, indicating a potential upside of 1,016.07%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Ocuphire Pharma is more favorable than Cellectar Biosciences.
Cellectar Biosciences has a net margin of 0.00% compared to Cellectar Biosciences' net margin of -59.44%. Cellectar Biosciences' return on equity of -24.57% beat Ocuphire Pharma's return on equity.
Ocuphire Pharma has higher revenue and earnings than Cellectar Biosciences. Ocuphire Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.
Cellectar Biosciences has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Ocuphire Pharma has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.
Cellectar Biosciences received 206 more outperform votes than Ocuphire Pharma when rated by MarketBeat users. However, 68.00% of users gave Ocuphire Pharma an outperform vote while only 56.07% of users gave Cellectar Biosciences an outperform vote.
16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 15.0% of Ocuphire Pharma shares are owned by institutional investors. 3.7% of Cellectar Biosciences shares are owned by company insiders. Comparatively, 8.7% of Ocuphire Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Cellectar Biosciences had 3 more articles in the media than Ocuphire Pharma. MarketBeat recorded 4 mentions for Cellectar Biosciences and 1 mentions for Ocuphire Pharma. Cellectar Biosciences' average media sentiment score of 1.87 beat Ocuphire Pharma's score of 1.15 indicating that Ocuphire Pharma is being referred to more favorably in the news media.
Summary
Ocuphire Pharma beats Cellectar Biosciences on 12 of the 18 factors compared between the two stocks.
Get Ocuphire Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCUP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocuphire Pharma Competitors List
Related Companies and Tools
